Ollivier to steer global strategic initiatives, reinforcing C-Path’s commitment to accelerating medical innovation and regulatory science.Continue reading
Author Archive: Roxan Olivas
C-Path’s TRxA Announces its 2024 Global Request for Proposals from Academic Investigators Working to Advance Drug Development Projects
NEW FUNDING OPPORTUNITY!
TUCSON, Ariz, January 22, 2024 – Critical Path Institute’s (C-Path) Translational Therapeutics Accelerator (TRxA) today announced its 2024 global Request for Proposals for its Breakthrough Research and Innovation in Drug Development Grants, also known as BRIDGe. Continue reading
C-Path to Lead New Task Force Aimed at Accelerating Drug Development for Mitochondrial and Inherited Metabolic Diseases
TUCSON, Ariz., January 11, 2024 — Critical Path Institute (C-Path) today announced the launch of a task force focused on accelerating drug development for mitochondrial and inherited metabolic diseases. The task force will lay the groundwork for specific solutions, offering valuable insights that aim to contribute to regulatory decision-making.Continue reading
C-Path Appoints Dr. Klaus Romero as New CEO
Longtime quantitative medicine and regulatory science expert to spearhead C-Path’s collaborative efforts in accelerating drug development.Continue reading
C-Path’s RDCA-DAP Program and PicnicHealth Announce Data Collaboration to Accelerate Rare Disease Research
TUCSON, Ariz., December 12, 2023 – Critical Path Institute (C-Path), a leader in advancing rare disease research, is pleased to announce a data collaboration with PicnicHealth, a patient-centered healthcare evidence generation company.Continue reading
C-Path Welcomes Mucopolysaccharidosis Clinical Trial Data Contribution from Children’s Hospital of Orange County into RDCA-DAP
TUCSON, Ariz., December 12, 2023 – C-Path (Critical Path Institute) is thrilled to announce a significant addition to its Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP®). Children’s Hospital of Orange County (CHOC) has generously contributed clinical trial data related to mucopolysaccharidosis (MPS), reinforcing the power of collaboration in advancing rare disease research.Continue reading
C-Path’s Pioneering Neuroscience Workshop Transforms the Landscape of Neurological Disorder Therapies
TUCSON, Ariz., Nov. 9, 2023 – Critical Path Institute (C-Path) is pleased to announce the release of a new peer-reviewed publication, titled “Transforming Drug Development for Neurological Disorders: Proceedings from a Multi-disease Area Workshop,” now published in Neurotherapeutics, The Journal of the American Society for Experimental Neurotherapeutics.Continue reading
C-Path’s T1D Consortium New-onset Article Published in The Lancet Diabetes and Endocrinology
Research confirms immune-based therapies improve outcomes in new-onset T1DContinue reading
C-Path and CHI Announce Data Sharing Agreement
TUCSON, Ariz., October 26, 2023 — Critical Path Institute (C-Path) and Congenital Hyperinsulinism International (CHI), a leading nonprofit dedicated to improving the lives of children and adults living with Congenital Hyperinsulinism (HI), today announced a data sharing agreement to incorporate rare disease patient-level data from CHI’s HI Global Registry into C-Path’s Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP®).Continue reading